The estimated Net Worth of Catherine Larue is at least $615 dollars as of 31 January 2023. Catherine Larue owns over 438 units of Quotient Ltd stock worth over $615 and over the last 4 years he sold QTNT stock worth over $0. In addition, he makes $0 as Independent Director at Quotient Ltd.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Catherine Larue QTNT stock SEC Form 4 insiders trading
Catherine has made over 10 trades of the Quotient Ltd stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 438 units of QTNT stock worth $166 on 31 January 2023.
The largest trade he's ever made was exercising 6,917 units of Quotient Ltd stock on 31 October 2022 worth over $2,628. On average, Catherine trades about 4,332 units every 75 days since 2020. As of 31 January 2023 he still owns at least 1,618 units of Quotient Ltd stock.
You can see the complete history of Catherine Larue stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Catherine Larue biography
Dr. Catherine Larue Ph.D. has been appointed as Independent Director of the Company effective 9/1/2020. She serves as Director of External Affairs at the Integrated Biobank of Luxemburg (IBBL), which is organized within the Luxemburg Institute of Health (LIH) and dedicated to supporting biomedical research, providing biospecimen and biobanking services and infrastructure for applied medical research. Dr. Catherine Larue began her career at Sanofi in the cardiovascular R&D department before joining Sanofi Diagnostics Pasteur in Minneapolis, Minnesota, where she was responsible for assay development on the Access instrument in the immunodiagnostic area. Dr. Larue also served as a Director of business unit at Bio-Rad Laboratories, Inc., and Executive Vice President of Biomarkers at GENFIT, before serving as CEO of IBBL. Dr. Larue has authored 87 publications (h index 19) and filed 13 patents, while also creating and chairing the “Biomarkers Group” in the Competitiveness Bio-cluster (Medicen, Paris). She sits on the boards of Fondation ARC, an organization of public utility focused on cancer research, Genfit a biopharmaceutical company, and Information Technology for Translational Medicine (ITTM S.A.), a clinical data processing company. Dr. Larue holds a Ph.D. in immunology from the University of Rouen and a Master in Business Administration from St. John’s University and ISM Paris.
How old is Catherine Larue?
Catherine Larue is 64, he's been the Independent Director of Quotient Ltd since 2020. There are 4 older and 10 younger executives at Quotient Ltd. The oldest executive at Quotient Ltd is John Wilkerson, 77, who is the Independent Director.
What's Catherine Larue's mailing address?
Catherine's mailing address filed with the SEC is C/O QUOTIENT LIMITED, BUSINESS PARK, TERRE BONNE, ROUTE DE CRASSIER 13, EYSINS, V8, 1262.
Insiders trading at Quotient Ltd
Over the last 11 years, insiders at Quotient Ltd have traded over $5,237,327 worth of Quotient Ltd stock and bought 21,364,813 units worth $72,052,006 . The most active insiders traders include Advisors Llcperceptive Life..., Zubeen Shroff és L John Wilkerson. On average, Quotient Ltd executives and independent directors trade stock every 15 days with the average trade being worth of $57,203. The most recent stock trade was executed by Catherine Larue on 31 January 2023, trading 438 units of QTNT stock currently worth $166.
What does Quotient Ltd's logo look like?
Complete history of Catherine Larue stock trades at Quotient Ltd
Quotient Ltd executives and stock owners
Quotient Ltd executives and other stock owners filed with the SEC include:
-
Franz Walt,
Chief Executive Officer, Director -
Edward Farrell,
Chief Operating Officer -
Jeremy Stackawitz,
Chief Commercial Officer -
Peter Buhler,
Chief Financial Officer -
Heino.N.F.M von Prondzynski,
Independent Chairman of the Board -
Frederick Hallsworth,
Independent Director -
Brian McDonough,
Independent Director -
Zubeen Shroff,
Independent Director -
John Wilkerson,
Independent Director -
Catherine Larue,
Independent Director -
Isabelle Buckle,
Independent Director -
Ernest Larnach,
Head - Financial Accounting & Treasury -
Esteban Uriarte,
Chief Manufacturing Operations Officer -
Mohammad El Khoury,
Chief Commercial Officer -
Christian Albrich,
Chief People Officer -
Dr. Christine Ginocchio,
Chief Scientific & Medical Officer -
Dr. Michael Hausmann,
Chief Technology Officer -
Vittoria Bonasso,
Head of Fin., Group Controller & Principal Accounting Officer -
Ali Kiboro,
Chief Financial Officer -
Manuel O. Mendez,
CEO & Director -
Ernest Larnach,
Head of Financial Accounting & Treasury -
Vittoria Bonasso,
See Remarks -
Roland Boyd,
See Remarks -
Thomas A Bologna,
Director -
Sarah A Oconnor,
Director -
Stephen Unger,
Chief Financial Officer -
Partners V Lp Galen Partner...,
-
Deidre Quotient Biodiagnost...,
-
D J Paul E Cowan,
See Remarks -
Sophie Bechu,
Director -
Advisors Llcperceptive Life...,
-
Christopher J Lindop,
EVP -
Ali Kiboro,
Chief Financial Officer -
Manuel O. Mendez,
Chief Executive Officer -
Khoury Mohammad El,
Chief Commercial Officer -
Thomas Aebischer,
Director